COSTAL CHONDROCYTE-DERIVED PELLET-TYPE AUTOLOGOUS CHONDROCYTE IMPLANTATION FOR TREATMENT OF ARTICULAR CARTILAGE DEFECT: A RANDOMIZED PHASE 3 CLINICAL TRIAL COMPARED TO MICROFRACTURE

Objective To compare the efficacy and safety of costal chondrocyte-derived pellet-type autologous chondrocyte implantation (CCP-ACI) with microfracture (MFx) for repair of articular cartilage defects of the knee. Design A total of 104 subjects with an International Cartilage Repair Society (ICRS) gr...

Full description

Saved in:
Bibliographic Details
Published inCytotherapy (Oxford, England) Vol. 26; no. 6; p. e3
Main Authors Lee, J., Lee, S., Park, J., Yoon, K.
Format Journal Article
LanguageEnglish
Published Elsevier Inc 01.06.2024
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Objective To compare the efficacy and safety of costal chondrocyte-derived pellet-type autologous chondrocyte implantation (CCP-ACI) with microfracture (MFx) for repair of articular cartilage defects of the knee. Design A total of 104 subjects with an International Cartilage Repair Society (ICRS) grade 3 or 4 chondral defect (2 to 10 cm2 in area; ≤ 4 cm3 in volume) were recruited and were randomly assigned at a 1:1 ratio to the CCP-ACI group and the MFx group. CCP-ACI was performed by harvesting costal cartilage about 6 weeks before surgery. Implantation was performed without any marrow stimulation. Efficacy and safety were assessed at weeks 8, 24, and 48 after surgery according to the magnetic resonance observation of cartilage repair tissue (MOCART) score and clinical outcomes. Results MOCART scores improved from baseline to 24 and 48 weeks postoperatively in both treatment groups. The MOCART scores in the CCP-ACI group was significantly greater than that in the MFx group at 24 and 48 weeks. The scores of complete defect repair, complete integration, and signal intensity of the repair tissue were significantly higher in the CCP-ACI group than the MFx group at 48 weeks. Clinical outcomes significantly improved at 24 and 48 weeks in both groups, but no statistical differences between the groups were observed. Conclusion The treatment of CCP-ACI for cartilage defects has yielded promising results, demonstrating excellent structural regeneration and positive clinical outcomes. <!– notionvc: bcd25fa6-f6f6-407e-8d22-b1e4101db7ac –>
AbstractList Background & AimObjective To compare the efficacy and safety of costal chondrocyte-derived pellet-type autologous chondrocyte implantation (CCP-ACI) with microfracture (MFx) for repair of articular cartilage defects of the knee. Methods, Results & ConclusionDesign A total of 104 subjects with an International Cartilage Repair Society (ICRS) grade 3 or 4 chondral defect (2 to 10 cm2 in area; ≤ 4 cm3 in volume) were recruited and were randomly assigned at a 1:1 ratio to the CCP-ACI group and the MFx group. CCP-ACI was performed by harvesting costal cartilage about 6 weeks before surgery. Implantation was performed without any marrow stimulation. Efficacy and safety were assessed at weeks 8, 24, and 48 after surgery according to the magnetic resonance observation of cartilage repair tissue (MOCART) score and clinical outcomes. Results MOCART scores improved from baseline to 24 and 48 weeks postoperatively in both treatment groups. The MOCART scores in the CCP-ACI group was significantly greater than that in the MFx group at 24 and 48 weeks. The scores of complete defect repair, complete integration, and signal intensity of the repair tissue were significantly higher in the CCP-ACI group than the MFx group at 48 weeks. Clinical outcomes significantly improved at 24 and 48 weeks in both groups, but no statistical differences between the groups were observed. Conclusion The treatment of CCP-ACI for cartilage defects has yielded promising results, demonstrating excellent structural regeneration and positive clinical outcomes. <!– notionvc: bcd25fa6-f6f6-407e-8d22-b1e4101db7ac –>
Objective To compare the efficacy and safety of costal chondrocyte-derived pellet-type autologous chondrocyte implantation (CCP-ACI) with microfracture (MFx) for repair of articular cartilage defects of the knee. Design A total of 104 subjects with an International Cartilage Repair Society (ICRS) grade 3 or 4 chondral defect (2 to 10 cm2 in area; ≤ 4 cm3 in volume) were recruited and were randomly assigned at a 1:1 ratio to the CCP-ACI group and the MFx group. CCP-ACI was performed by harvesting costal cartilage about 6 weeks before surgery. Implantation was performed without any marrow stimulation. Efficacy and safety were assessed at weeks 8, 24, and 48 after surgery according to the magnetic resonance observation of cartilage repair tissue (MOCART) score and clinical outcomes. Results MOCART scores improved from baseline to 24 and 48 weeks postoperatively in both treatment groups. The MOCART scores in the CCP-ACI group was significantly greater than that in the MFx group at 24 and 48 weeks. The scores of complete defect repair, complete integration, and signal intensity of the repair tissue were significantly higher in the CCP-ACI group than the MFx group at 48 weeks. Clinical outcomes significantly improved at 24 and 48 weeks in both groups, but no statistical differences between the groups were observed. Conclusion The treatment of CCP-ACI for cartilage defects has yielded promising results, demonstrating excellent structural regeneration and positive clinical outcomes. <!– notionvc: bcd25fa6-f6f6-407e-8d22-b1e4101db7ac –>
Author Park, J.
Lee, J.
Yoon, K.
Lee, S.
Author_xml – sequence: 1
  givenname: J.
  surname: Lee
  fullname: Lee, J.
  organization: R&D iInstitute, Bio Solution Co, Ltd, Seoul, Korea (the Republic of)
– sequence: 2
  givenname: S.
  surname: Lee
  fullname: Lee, S.
  organization: R&D iInstitute, Bio Solution Co, Ltd, Seoul, Korea (the Republic of)
– sequence: 3
  givenname: J.
  surname: Park
  fullname: Park, J.
  organization: CHA Bundang Medical Center, Seoul, Please Select, Korea (the Republic of)
– sequence: 4
  givenname: K.
  surname: Yoon
  fullname: Yoon, K.
  organization: Kyung-Hee University, Seoul, Please Select, Korea (the Republic of)
BookMark eNqFUWGL1DAQLXKCd6d_wE_5A12TtE27hwghTW8LbbNkU-H8EmKahda1K-2dsD_M_2fC-UEEFQZmYOa9efPmJrqaz7OLorcIbhBE5N20mezlcYMhTjfQB0peRNcozfMYZ4RchZpkcYLT7avoZl0nCDEsiuw6-sHEQdEGsJ3oSinYg-JxyWX9kZdgz5uGq1g97DmgvRKNuBf94fdRULf7hnaKqlp0oBISKMmpanmngKgAlapmfUMlYKFs6D0HJa84U3eAAkm7UrT1p7BpRw8cJIA1dVczL0fJOogS7Z5K31cCtDWTopKUqV7y19HLozmt7s2vfBv1FVdsF3uJAR9b70Ti7zWDwy4xJkfI2dRtHYEwM8YhbKEZ8iEvSFJk221hPhNXkCGD2BJjMHJHl7vkNsLPvHY5r-vijvrbMn41y0UjqIPxetLBeB2M19AHSjzo_TPIeWXfR7fo1Y5utm4YF2cf9XAe_w3_8AfcnsZ5tOb0xV3cOp2fltnfrJFesYb6ED4bHotTCAlOiCe4-zvB_7b_BDMwqeI
ContentType Journal Article
Copyright 2024
Copyright_xml – notice: 2024
DBID AAYXX
CITATION
DOI 10.1016/j.jcyt.2024.04.013
DatabaseName CrossRef
DatabaseTitle CrossRef
DatabaseTitleList


DeliveryMethod fulltext_linktorsrc
Discipline Pharmacy, Therapeutics, & Pharmacology
EISSN 1477-2566
EndPage e3
ExternalDocumentID 10_1016_j_jcyt_2024_04_013
S1465324924006236
1_s2_0_S1465324924006236
GroupedDBID ---
--M
.1-
.FO
.~1
1P~
1~.
29F
36B
4.4
457
4G.
53G
5GY
5VS
7-5
8P~
AAAJQ
AAEDT
AAEDW
AAIKJ
AAKOC
AALRI
AAOAW
AATTM
AAXKI
AAXUO
AAYWO
ABDBF
ABGSF
ABJNI
ABMAC
ABMZM
ABUDA
ABXDB
ACDAQ
ACGEJ
ACGFS
ACIEU
ACRLP
ACUHS
ACVFH
ADBBV
ADCNI
ADCVX
ADEZE
ADXPE
AEBSH
AEHWI
AEIPS
AEKER
AENEX
AEUPX
AEVXI
AFJKZ
AFKVX
AFPUW
AFRHN
AFTJW
AFXIZ
AGCQF
AGEKW
AGHFR
AGRDE
AGUBO
AGYEJ
AIEXJ
AIGII
AIIUN
AIKHN
AITUG
AJRQY
AJUYK
AJWEG
AKBMS
AKRWK
AKYEP
ALMA_UNASSIGNED_HOLDINGS
AMRAJ
ANKPU
ANZVX
APXCP
ASPBG
AVWKF
AWYRJ
AXJTR
AZFZN
BKOJK
BLXMC
BNPGV
CAG
CJTIS
COF
CS3
DU5
EAP
EBC
EBS
EFJIC
EFKBS
EJD
EMB
EMK
EMOBN
ESX
F5P
FDB
FEDTE
FGOYB
FIRID
FNPLU
FYGXN
GBLVA
H13
HVGLF
HZ~
KOM
LUGTX
M44
MO0
O-L
O9.
OAUVE
OK~
P-8
P-9
P2P
PC.
Q38
R2-
ROL
SDF
SPCBC
SSH
SSI
SSU
SSZ
SV3
T5K
TDBHL
TFW
Z5R
~G-
AACTN
AFCTW
AFKWA
AJOXV
AMFUW
AAIAV
AAYXX
AGRNS
CITATION
ID FETCH-LOGICAL-c2023-32ade2e3aa711ec4e9e6005aae12c0ad7d786385998ab6e86d502c6aa21efe7e3
IEDL.DBID .~1
ISSN 1465-3249
IngestDate Tue Jul 01 03:32:40 EDT 2025
Sat Jun 29 15:31:21 EDT 2024
Sun Feb 23 10:18:43 EST 2025
Tue Aug 26 16:48:42 EDT 2025
IsPeerReviewed true
IsScholarly true
Issue 6
Keywords clinical trial
autologous chondrocyte
cartilage regeneration
Language English
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c2023-32ade2e3aa711ec4e9e6005aae12c0ad7d786385998ab6e86d502c6aa21efe7e3
ParticipantIDs crossref_primary_10_1016_j_jcyt_2024_04_013
elsevier_sciencedirect_doi_10_1016_j_jcyt_2024_04_013
elsevier_clinicalkeyesjournals_1_s2_0_S1465324924006236
elsevier_clinicalkey_doi_10_1016_j_jcyt_2024_04_013
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate June 2024
PublicationDateYYYYMMDD 2024-06-01
PublicationDate_xml – month: 06
  year: 2024
  text: June 2024
PublicationDecade 2020
PublicationTitle Cytotherapy (Oxford, England)
PublicationYear 2024
Publisher Elsevier Inc
Publisher_xml – name: Elsevier Inc
SSID ssj0020885
Score 2.384561
Snippet Objective To compare the efficacy and safety of costal chondrocyte-derived pellet-type autologous chondrocyte implantation (CCP-ACI) with microfracture (MFx)...
Background & AimObjective To compare the efficacy and safety of costal chondrocyte-derived pellet-type autologous chondrocyte implantation (CCP-ACI) with...
SourceID crossref
elsevier
SourceType Index Database
Publisher
StartPage e3
SubjectTerms Advanced Basic Science
autologous chondrocyte
cartilage regeneration
clinical trial
Other
Title COSTAL CHONDROCYTE-DERIVED PELLET-TYPE AUTOLOGOUS CHONDROCYTE IMPLANTATION FOR TREATMENT OF ARTICULAR CARTILAGE DEFECT: A RANDOMIZED PHASE 3 CLINICAL TRIAL COMPARED TO MICROFRACTURE
URI https://www.clinicalkey.com/#!/content/1-s2.0-S1465324924006236
https://www.clinicalkey.es/playcontent/1-s2.0-S1465324924006236
https://dx.doi.org/10.1016/j.jcyt.2024.04.013
Volume 26
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwELaqcuGCeIqlUPmAeqFhYzuPhZuVOGwgm0RZL2q5WI7jSu1hqdhy2Av_iv_HeJO0RVQgIeWQh8e2POPxjDPzGaHXAfUZs8z3TGRaLzC082aaMC8yDJyJOIrPrEsUXpTRfBV8PAlP9lAy5sK4sMpB9_c6faethzfTYTSnl-fn0yVx0GAO8C5wiYDMwW4HUDvI9Nsf12EeFGZR2GcYhZ4rPSTO9DFeF2br4ilpsIM7JezuxenWgpM9RA8GSxHzvjOP0J5dP0ZHdQ81vT3G8iZzanOMj3B9A0K9fYJ-JtVS8gIn86pMmyo5lcJLwWn7LFJci6IQ0pOntcAgn-5XUrVa3i6K80Vd8FLuNrAwOIpYNoJLB_yPqwyDEZwnq4I3OHG3Bf8gcCoykcj3mOOGl2m1yL-4luZ8KTDDSZGXDngBqsldp6pFzRv4LisMYtBUWcMTF3_xFK0yIZO5NxzR4Bl37jqMqO4stUzrmBBrAvvOggUVam0JNb7u4i6ewQwPwanTbWRnURf61ERaU2LPbGzZM7S__rq2zxHWHaFtC-ZpHIQB084RA9fMtKCBjAlZMEFvRt6oyx6JQ40hahfKcVI5TiofLsImiI3sU2OOKWhFBQvFX6niu6jsZpjYG0XUhipf_SF8ExReU_4mv_9o8cV_0h2g--6pD1p7ifavvn23r8A8umoPd_J_iO7x_NO8_AUYcAE0
linkProvider Elsevier
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwELbK9gAXxFNsefmAeqHRxnEeCzcr8ZLQvJT1opaL5Tiu1B6Wii2H_WH8P8abpC2iAgkphyjOxJbn4Rln5jNC73zPpdRQ19Ghbh1fe50zV4Q6oaYQTERhdGZsoXBRhunK_3wSnOyheKyFsWmVg-3vbfrOWg9PZsNszi7Pz2dLYqHBLOCdbwsBaXgP7Vt0qmCC9ll2nJbXcRcoUtAXGQWOJRhqZ_o0rwu9tSmVnr9DPCX07vXp1pqzeIQeDs4iZv14HqM9s36CDusebXp7hMVN8dTmCB_i-gaHevsU_YyrpWA5jtOqTJoqPhXcSSBu-8ITXPM858IRpzXHIKL2b1K1Wt5-FWdFnbNS7PawMMSKWDScCYv9j6sFBj84i1c5a3Bsb3P2ieOEL3gsPmKGG1YmVZF9tT2lbMkxxXGelRZ7AT6T2UFVRc0aaBcVBkloqkXDYpuC8QytFlzEqTOc0uBoe_Q6zKjqjGeoUhEhRvvmgwEnKlDKEE-7qou6aA5KHkBcp9rQzMMucD0dKuURc2YiQ5-jyfrb2rxAWHXEa1vwUCNgJFU2FoPoTLdghLQOqD9F70feyMsejEOOWWoX0nJSWk5KFy5Cp4iO7JNjmSkYRglrxV-poruozGbQ7Y0kcuNJV_4hf1MUXFP-JsL_6PHgP-neovupKHIJ7Dt-iR7Ylj6H7RWaXH3_YV6Dt3TVvhm04RcCOgPl
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=COSTAL+CHONDROCYTE-DERIVED+PELLET-TYPE+AUTOLOGOUS+CHONDROCYTE+IMPLANTATION+FOR+TREATMENT+OF+ARTICULAR+CARTILAGE+DEFECT%3A+A+RANDOMIZED+PHASE+3+CLINICAL+TRIAL+COMPARED+TO+MICROFRACTURE&rft.jtitle=Cytotherapy+%28Oxford%2C+England%29&rft.au=Lee%2C+J&rft.au=Lee%2C+S&rft.au=Park%2C+J&rft.au=Yoon%2C+K&rft.date=2024-06-01&rft.issn=1465-3249&rft.volume=26&rft.issue=6&rft.spage=e3&rft.epage=e3&rft_id=info:doi/10.1016%2Fj.jcyt.2024.04.013&rft.externalDBID=ECK1-s2.0-S1465324924006236&rft.externalDocID=1_s2_0_S1465324924006236
thumbnail_m http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=https%3A%2F%2Fcdn.clinicalkey.com%2Fck-thumbnails%2F14653249%2FS1465324924X00067%2Fcov150h.gif